Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,080 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS-CoV-2 Pneumonia Clear all
Withdrawn Phase 2 Interventional

Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela

NCT04905888
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric oxygen therapy
Combination Product
Lead sponsor
Peter Lindholm
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 17, 2026, 2:54 PM EDT
Completed No phase listed Observational

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

NCT07090486
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 17, 2026, 2:54 PM EDT
Completed No phase listed Observational

Investigating Immune Escape by SARS-CoV-2 Variants

NCT05171803
View directory record Official record
Conditions
COVID-19; Immunity
Interventions
No intervention
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Dimas, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

NCT05122260
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin, Placebo
Drug · Other
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 17, 2026, 2:54 PM EDT
Withdrawn No phase listed Observational

ImmuneSense™ COVID-19 Cross-Reactivity Study

NCT05112874
View directory record Official record
Conditions
Coronavirus Disease, SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 17, 2026, 2:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)

NCT07770022
View directory record Official record
Conditions
Long Covid
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298
View directory record Official record
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 17, 2026, 2:54 PM EDT
Not yet recruiting Not applicable Interventional

Harnessing Optimism and Perseverance in the Face of Long COVID-Español

NCT07216040
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
HOPE-LC~Espanol
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Completed No phase listed Observational

Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions

NCT04348240
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276
View directory record Official record
Conditions
Covid-19 Prevention
Interventions
Ad26.COV2.S, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 17, 2026, 2:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07536308
View directory record Official record
Conditions
COVID-19
Interventions
OCU500
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Decatur, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04463004
View directory record Official record
Conditions
COVID-19, Sars-CoV2, Pneumonia
Interventions
Mavrilimumab, Placebos
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

NCT04931004
View directory record Official record
Conditions
Covid19
Interventions
Mouthwash Product
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure

NCT04319731
View directory record Official record
Conditions
SARS CoV-2 Infection
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 17, 2026, 2:54 PM EDT
Completed Phase 2 Interventional

A Study of Quintuple Therapy to Treat COVID-19 Infection

NCT04334512
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, Coronavirus-19, Sars-CoV2
Interventions
Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 17, 2026, 2:54 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 17, 2026, 2:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Short Term Corticosteroids in SARS-CoV2 Patients

NCT04445506
View directory record Official record
Conditions
Corticosteroids, Covid19, SARS-CoV 2, Steroids, Dexamethasone
Interventions
Dexamethasone
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Sep 17, 2026, 2:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers

NCT04370821
View directory record Official record
Conditions
Occupational Exposure to SARS-CoV-2, COVID-19
Interventions
Not listed
Lead sponsor
Villanova University
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 17, 2026, 2:54 PM EDT